Article | Published:

Induction of angiogenesis in a mouse model using engineered transcription factors

Nature Medicine volume 8, pages 14271432 (2002) | Download Citation

Subjects

Abstract

The relationship between the structure of zinc-finger protein (ZFP) transcription factors and DNA sequence binding specificity has been extensively studied1. Advances in this field have made it possible to design ZFPs de novo that will bind to specific targeted DNA sequences2,3,4,5,6,7,8,9,10. It has been proposed that such designed ZFPs may eventually be useful in gene therapy6,7,10. A principal advantage of this approach is that activation of an endogenous gene ensures expression of the natural array of splice variants2. Preliminary studies in tissue culture have validated the feasibility of this approach2,3,4. The studies reported here were intended to test whether engineered transcription factors are effective in a whole-organism model. ZFPs were designed to regulate the endogenous gene encoding vascular endothelial growth factor-A (Vegfa). Expression of these new ZFPs in vivo led to induced expression of the protein VEGF-A, stimulation of angiogenesis and acceleration of experimental wound healing. In addition, the neovasculature resulting from ZFP-induced expression of Vegfa was not hyperpermeable as was that produced by expression of murine Vegfa164 cDNA. These data establish, for the first time, that specifically designed transcription factors can regulate an endogenous gene in vivo and evoke a potentially therapeutic biophysiologic effect.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Design and selection of novel Cys2His2 zinc finger proteins. Annu. Rev. Biochem. 70, 313–340 (2001).

  2. 2.

    et al. Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J. Biol. Chem. 276, 11323–11334 (2001).

  3. 3.

    et al. Synthetic zinc finger transcription factor action at an endogenous chromosomal site. Activation of the human erythropoietin gene. J. Biol. Chem. 275, 33850–33860 (2000).

  4. 4.

    , , & Toward controlling gene expression at will: Specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc. Natl. Acad. Sci. USA 95, 14628–14633 (1998).

  5. 5.

    , & In vitro selection of zinc fingers with altered DNA-binding specificity. Biochemistry 33, 5689–5695 (1994).

  6. 6.

    & Zinc finger–DNA recognition: Crystal structure of a Zif268-DNA complex at 2.1 Å. Science. 252, 809–817 (1991).

  7. 7.

    & Selection of DNA binding sites for zinc fingers using rationally randomized DNA reveals coded interactions. Proc. Natl. Acad. Sci. USA 91, 11168–11172 (1994).

  8. 8.

    & A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. Science 275, 657–661 (1997).

  9. 9.

    & Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins. Proc. Natl. Acad. Sci. USA 90, 2256–2260 (1993).

  10. 10.

    & Zinc finger phage: Affinity selection of fingers with new DNA-binding specificities. Science 263, 671–673 (1994).

  11. 11.

    Chromatin Structure and Function (Academic Press, London, 1998).

  12. 12.

    et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80, 99115 (2000).

  13. 13.

    et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nature Med. 6, 460–463 (2000).

  14. 14.

    et al. Wound healing in MIP-1−/− and MCP-1−/− mice. Am. J. Pathol. 159, 457–463 (2001).

  15. 15.

    , , , & Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol. Cell. Biol. 20, 7282–7291 (2000).

  16. 16.

    et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1. Genes Dev. 15, 2520–2532 (2001).

  17. 17.

    et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med. 2, 534–539 (1996)

  18. 18.

    et al. Left ventricular electromechanical mapping to assess efficacy of hVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102, 965–974 (2000).

  19. 19.

    et al. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100, 468–474 (1999).

  20. 20.

    et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor. Circulation. 102, 2255–2262 (2000).

  21. 21.

    et al. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509–2514 (1998).

  22. 22.

    et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl. Acad. Sci. USA 98, 5780–5785 (2001).

Download references

Acknowledgements

The authors thank A. Wolffe whose essential scientific input and discussions made this work possible; C. Pabo for scientific input and helpful comments on the manuscript; E. Lanphier and D. Bobo for supporting the ZFP concept; and A. Vincent for technical assistance. This work was funded by an American Heart Association award (AHA no. 97-30083N), by US National Institutes of Health grant RO1-HL64001 and by an unrestricted gift from Edwards Lifesciences (all to F.J.G.).

Author information

Author notes

    • Edward J. Rebar
    •  & Yan Huang

    These authors contributed equally to this work.

Affiliations

  1. Sangamo Biosciences, Richmond, California, USA

    • Edward J. Rebar
    • , Bingliang Chen
    • , Lei Xu
    • , Yuxin Liang
    • , Andrew C. Jamieson
    • , Lei Zhang
    • , S Kaye Spratt
    • , Casey C. Case
    •  & Alan Wolffe
  2. Dept. of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

    • Yan Huang
    • , Reed Hickey
    • , Anjali K. Nath
    • , David Meoli
    • , Sameer Nath
    •  & Frank J. Giordano

Authors

  1. Search for Edward J. Rebar in:

  2. Search for Yan Huang in:

  3. Search for Reed Hickey in:

  4. Search for Anjali K. Nath in:

  5. Search for David Meoli in:

  6. Search for Sameer Nath in:

  7. Search for Bingliang Chen in:

  8. Search for Lei Xu in:

  9. Search for Yuxin Liang in:

  10. Search for Andrew C. Jamieson in:

  11. Search for Lei Zhang in:

  12. Search for S Kaye Spratt in:

  13. Search for Casey C. Case in:

  14. Search for Alan Wolffe in:

  15. Search for Frank J. Giordano in:

Competing interests

E.J.R., B.C., L.X., Y.L., A.C.J., L.Z., K.S., C.C.C. and A.W. have potential competing interests in that they are employees of Sangamo Biosciences, which could benefit from the publication of this data.

Corresponding author

Correspondence to Frank J. Giordano.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm1202-795

Further reading